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Abstract
Background: Cholangiocarcinomas are uncommon tumours with a poor
prognosis, that frequently present epidermal growth factor receptor
overexpression. Methods: In a multi-centre phase II trial, patients with
unresectable cholangiocarcinoma, naïve to chemotherapy, received Cetuximab
(400 mg/m2 at week 1, then 250 mg/m2/week) and Gemcitabine (1 g/m2 on day
1, 8 and 15 every 4 weeks). Primary end point was progression-free survival
(PFS) rate at 6 months, using a Simon 2-stage design. Moreover, we assessed
the impact of KRAS status and skin toxic effect on efficacy. Results: Forty-
four patients (41% locally advanced/59% metastatic) were enrolled. Median age
was 61.5 years; ECOG PS was 0 (68%) or 1. Six months PFS reached 47%.
Median OS was 13.5 months [95% confidence interval (CI) 9.8-31.8 months].
Nine patients (20.4%) had PR and disease-control rate was 79.5%. Grade 3/4-
related toxic effects were haematological (52.2%), skin rash (13.6%) and fatigue
(11.4%). KRAS mutations were found i...
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Background: Cholangiocarcinomas are uncommon tumours with a poor prognosis, that frequently present epidermal
growth factor receptor overexpression.
Methods: In a multi-centre phase II trial, patients with unresectable cholangiocarcinoma, naïve to chemotherapy,
received Cetuximab (400 mg/m2 at week 1, then 250 mg/m2/week) and Gemcitabine (1 g/m2 on day 1, 8 and 15 every 4
weeks). Primary end point was progression-free survival (PFS) rate at 6 months, using a Simon 2-stage design. Moreover,
we assessed the impact of KRAS status and skin toxic effect on efﬁcacy.
Results: Forty-four patients (41% locally advanced/59% metastatic) were enrolled. Median age was 61.5 years; ECOG
PS was 0 (68%) or 1. Six months PFS reached 47%. Median OS was 13.5 months [95% conﬁdence interval (CI)
9.8–31.8 months]. Nine patients (20.4%) had PR and disease-control rate was 79.5%. Grade 3/4–related toxic effects
were haematological (52.2%), skin rash (13.6%) and fatigue (11.4%). KRAS mutations were found in 7 of 27 patients and
had no inﬂuence on PFS. Skin toxic effect ≥grade 2 was associated with increased PFS (P = 0.05).
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Conclusion(s): Our study met its primary end point, suggesting that Gemcitabine-Cetuximab has activity in
cholangiocarcinoma. KRAS status was not associated with PFS, unlike skin toxic effect, which could be used as a
surrogate marker for efﬁcacy.
ClinicalTrials.gov Identiﬁer: NCT00747097.
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introduction
Cholangiocarcinomas (CCK) are uncommon tumours arising as
a result of neoplastic transformation of bile duct epithelial cells
[1]. They can be divided into intra-hepatic tumours, hilar
(klatskin) and common bile duct tumours [2]. CCK remains the
second most common hepatobiliary cancer (≈5000 new cases
annually in the United States) [3] and its detection rate is
increasing due to a better knowledge of the disease and
improved diagnosis [4]. Hilar tumour still represents the most
commonn form of CCK but the intra-hepatic form is steadily
increasing in incidence since the seventies [3].The only curative
treatment of CCK is surgery, feasible in only 30% of patients.
Furthermore, patients who undergo curative surgery experience
a high recurrence rate [5]. Chemoradiation followed by liver
transplantation is an option for selected patients [6]. Until
recently, there was no recognized standard treatment of
advanced CCK, due to a lack of consideration of this rare
disease for large phase III randomized, controlled trials (RCT).
The nucleoside analogue gemcitabine (Gem) has shown activity,
either in monotherapy or in combination with other cytostatic
drugs [7]. Recently, a phase III RCT (ABC-02) has shown that
the combination cisplatin-Gem led to signiﬁcant improvements
in overall survival (OS) (median 11.7 versus 8.1 months,
P < 0.001) and in progression-free survival (PFS) (median 8.0
versus 5.0 months, P < 0.001) versus Gem [8]. The epidermal
growth factor receptor (EGFR) expression and activation is
involved in many epithelial tumours’ growth. EGFR is
frequently overexpressed [9] and/or mutated [10] in CCKs.
Mutations of KRAS and BRAF, effectors of the EGFR pathway,
have also been reported [9]. Therefore, targeting EGFR is an
attractive therapeutic approach. Cetuximab (Ctx) is a
chimerized IgG1 monoclonal antibody which blocks binding of
EGF and TGFα to the EGFR. A phase II trial investigating Ctx
in combination with Gem and oxaliplatin (GEMOX) in CCK
showed an objective response rate of 63% [11]. Recently, the
randomized phase 2 BINGO trial failed to show a signiﬁcant
improvement of adding Ctx to the GEMOX regimen [12]. Other
targeted therapies have been explored in phase II trials: the
VEGF-targeting antibody bevacizumab, combined with
GEMOX, led to a 7.0 months median PFS [13]; a phase III RCT
failed to demonstrate the efﬁcacy of GEMOX +/− erlotinib, an
EGFR tyrosine kinase inhibitor, in CCK and gallbladder
adenocarcinoma. However, a sub-analysis showed that CCK
patients experienced a prolonged median PFS: 5.9 versus 3.0
months, P = 0.049 [14]. At the time we designed this phase II
study combining Ctx and Gem in ﬁrst-line treatment of
advanced CCK, the ABC-02 study results were unknown;
therefore, we did not assess the combination of Gem-platinum
to Ctx. The primary objective of this trial was the PFS rate at 6
months; secondary objectives included OS, response rate and
safety. Exploratory objectives were to assess relationship




All patients had a histologically or cytologically conﬁrmed CCK, excluding
gallbladder cancer, that was either unresectable or metastatic. Eligibility
criteria were measurable disease according to Response Evaluation Criteria
in Solid Tumors (RECIST), ECOG performance status (PS) 0 or 1; estimated
life expectancy ≥12 weeks; adequate liver (total bilirubin ≤2× the upper
limit of normal (ULN) range); renal (serum creatinin <1.5× ULN range) and
haematopoietic (Hb >9 g/dl, absolute neutrophil count >1.500/mm3 and
platelets >100 000/mm3) functions. All patients with jaundice underwent an
adequate bile duct drainage. Exclusion criteria were previous radiation
therapy, therapies targeting the EGF pathway or any other systemic
treatment of CCK; history of malignancy within the previous 5 years (except
for adequately treated basal cell skin cancer and in situ cervix cancer); HIV;
infectious or uncontrolled concurrent CNS diseases; cardiac diseases.
Informed Consent document were signed after appropriate explanations
of the study and alternate treatments.
treatment plan
The trial regimen consisted on the administration of Ctx (Erbitux®, Merck,
Darmstadt), at the initial dose of 400 mg/m2 in a 120-min i.v. infusion and
further injections of 250 mg/m2 in a 60 min i.v. infusion every 7 days
followed after 1-hour rest by Gem (Gemzar®, Eli-Lilly, IN), 1000 mg/m2,
administrated in a 30-min i.v. infusion on days 1, 8 and 15 every 4 weeks,
i.e., one cycle. Pre-treatment with anti-histaminic drugs and corticosteroids
was required before each Ctx injection to prevent allergic reactions. Reasons
for discontinuation included disease progression, unacceptable toxic effect
and patient or clinician choice. Ctx was provided by Merck and Gem was
provided by Eli-Lilly.
pre-treatment evaluation
Pre-treatment examinations were carried out within 5 weeks before starting
treatment and included performance status (PS), physical examination,
concomitant medications, biological evaluation of liver, renal and
haematopoietic functions, CA 19.9 and CEA dosages, pregnancy test for
women with a childbearing potential, ECG and thoraco-abdominal
computerized tomography (CT)-scan [or magnetic resonance imaging
(MRI)] for tumour assessment. Data regarding tumour diagnosis were also
collected: date, histology and staging.
safety assessment and dose adjustments
Patients were carefully evaluated for treatment-related toxic effects according
to the National Cancer Institute Common Toxicity Criteria for Adverse
Events (NCI-CTCAE) version 3.0. The worst grade of toxic effect per patient
was recorded. Patients were examined before each treatment administration
for PS assessment, blood analysis and monitoring of side-effects. In cases of
non-haematologic toxic effects >2, Gem was held until toxic effect ≤2 and
led to a subsequent dose reduction of 75% (grade 3) or 50% (grade 4) of the
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initial dose. For haematologic toxic effects, Gem was held, then reduced to
75% (grade 3 neutropenia, grade 2 thrombocytopenia) and to 50% (grade 4
neutropenia, grades 3–4 thrombocytopenia). Ctx dose was held if grade 3
skin toxic effect occurred, then reduced to 200 mg/m2 after the second
occurrence and to 150 mg/m2 after the third occurrence. If >2 consecutive
infusions were withheld, or a fourth occurrence of grade 3 skin toxic effect
occurred despite dose reduction, or in case of a grade 3 or 4 allergic/
hypersensitivity reaction, Ctx was permanently discontinued.
disease assessment
During the study, tumour imaging (CT/MRI) was carried out every 2
months. Disease response was evaluated by RECIST (version 1.1). PFS was
deﬁned as the time from the ﬁrst day of treatment to the date of objective
tumour/clinical progression or death, whichever occurs ﬁrst. PFS for
subjects without progression at the time of analysis was censored at the date
of last tumour assessment. Patients were considered to have achieved disease
stabilization if at least one stable disease (SD) assessment >6 weeks after start
of treatment was met. Duration of SD was calculated from ﬁrst day of
treatment until the criteria for disease progression is met. Disease control
rate (DCR) was deﬁned as the proportion of patients with a best overall
response of CR or PR or SD achieved during treatment. Duration of
response was calculated from the date of the ﬁrst documented response (CR
or PR) to the date of progression. OS was deﬁned as the time from the ﬁrst
day of treatment to death. OS of subjects alive at the time of analysis was
censored at the last date known to be alive.
KRAS mutational status assessment
Mutations in codons 12 and 13 of the KRAS gene were detected by
pyrosequencing of polymerase chain reaction (PCR) products that were
ampliﬁed from tumour DNA extracted from representative tumour tissue.
Tumour tissue, on formalin-ﬁxed parafﬁn-embedded slides, came from
either ﬁne-needle aspiration or core biopsy and resected surgical specimens.
statistical analysis
The primary end point of the trial was the proportion of patients who were
progression free at 24 weeks. The number of patients required for the trial
was determined according to a two-stage Simon design. Assuming an
increase of PFS rate at 24 weeks, from 20% with Gem, based on available
data, up to 40% with combination (type I error of 0.05 and type II error of
0.2), three patients without disease progression at 24 weeks had to be
observed in the ﬁrst 13 patients to allow the completion of the study,
including 43 patients.
Secondary end points included OS response rate and safety proﬁle.
Median time to event end points were estimated using the Kaplan–Meier
methodology. The 95% conﬁdence interval (CI) of the median time was also
estimated. For the exploratory analyses, the comparison of PFS and OS
according to skin toxic effect and KRAS mutational status groups was
carried out using the log-rank test.
results
patient characteristics
A total of 44 patients from nine Belgian institutions afﬁliated to
the Belgian Group of Digestive Oncology were enrolled over 18
months (September 2008 to January 2010). Patients (59.1%
male) were age 40–86 years old (mean 61.3 years). Baseline
ECOG PS was 0 (30 patients, 68.2%) and 1 (14 patients, 31.8%).
Nineteen patients (43.2%) underwent prior surgery and 26
(59.1%) were metastatic at study entry. Sixty-one percent of the
patients had intrahepatic CCK (Table 1).
gemcitabine and cetuximab administrations
Patients received a total of 310 cycles of treatment (mean: 7,
range: 1–34 cycles per patient). Sixty-one percent of patients
received between two and six cycles of study treatment. The
mean treatment duration was 22.1 weeks (range: 2–149.4
weeks). For 15 patients (34.1%), Gem dose remained
unchanged, while it was reduced for three patients (6.8%) and
both reduced and delayed for 11 patients (25.0%). Fourteen
patients (31.8%) had a Gem dose reduction and 26 patients a
dose temporary interruption, both mostly due to haematological
toxic effect. Ctx treatment was delayed in 7 patients (15.9%),
both reduced and delayed in 3 (6.8%) and interrupted in 10
(22.7%), mainly due to dermatologic events.
toxic effect
At the time of analysis (30 June 2012), all patients had
discontinued from study treatment. Reasons for discontinuation
were disease progression for 34 patients (77.3%), toxic effect for
6 (13.6%), patient’s request for 2 (4.5%) and investigator’s
decision for 2 (4.5%). All patients were assessable for toxic
effect. Table 2 summarizes all adverse reactions during the trial,
split by toxic effect grading. All patients reported at least one
grade 1–2 adverse event (AE), while 26 patients (59.1%) had at
least one grade 3–4 AE. Most frequent grades 3–4 AEs were
haematologic abnormalities (52.2%), biliary tract infections
(15.9%, considered to be related to study disease), skin toxic effect
(13.6%) and fatigue (11.4%). There were no treatment-related
deaths. Six patients (13.6%) discontinued study treatment
because of toxic effect: two patients for prolonged grade 3 skin
toxic effect, one for grade 4 skin toxic effect, two for haemolytic
uraemic syndrome (HUS) and one for nephrotic syndrome.
Table 1. Demographic and baseline characteristics of the patients (n = 44)
Age (years)




ECOG performance status, n (%)
0 30 (68.2)
1 14 (31.8)
Site of primary disease, n (%)
Intra-hepatic bile duct 27 (61.4)
Distal bile duct 5 (11.4)
Hilar bile duct 12 (27.3)
Extent of disease, n (%)
Locoregional 18 (40.9)
Metastatic 26 (59.1)
Prior surgery, n (%)
Yes 19 (43.2)
No 25 (56.8)
ECOG, Eastern Cooperative Oncology Group.
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efﬁcacy and patient’s outcome
Forty-three patients had a response assessment (S1,
supplementary Table S1, available at Annals of Oncology
online). Nearly 47% of the patients were progression-free at 6
months. The median PFS time was 5.8 months (95% CI 3.6–8.5
months). (Figure 1A). The median OS time (Figure 1B) was
13.5 months (95% CI 9.8–31.8 months) with 53.7% of patients
alive at 1 year. At the time of analysis, eight patients (18.2%)
were still alive. Nine patients achieved PR (20.4%) with a
median duration of 8 months (95% CI 2–31.0 months). Among
these responders, ﬁve and three patients experienced a grade 2
and 3 skin toxic effect patients, respectively. Twenty-six patients
(59.1%) achieved SD with a median duration of 6.0 months
(95% CI 5.0–12.0 months). The estimated DCR was 79.5%, for a
median time of 7 months (95% CI 4.0–12.0 months). PFS and
OS were not statistically different between patients with extra-
hepatic CCK (5.7 and 12.0 months, respectively) and intra-
hepatic CCK (7.1 and 14.3 months) (log-rank test; P = 0.773
and P = 0.555, respectively).
skin toxic effect and response
Of the 44 patients, 7 (15.9%) had no skin toxic effect, 9 (20.5%)
had grade 1 and 28 (63.3%) ≤grade 2 toxic effect. The median
PFS time was 7.7 months (95% CI 5.7–12.0 months) in patients
with a skin toxic effect ≥grade 2 and 3.3 months (95% CI 1.8–
5.3 months) in patients with a skin toxic effect ≤grade 1 (log-
rank test; P = 0.05), as shown in Figure 1C. The median OS time
was also longer in patients with a skin toxic effect ≥grade 2
compared with patients with a skin toxic effect ≤grade 1: 18.2







Any AE 44 (100.0) 26 (59.1) 44 (100.0)
Haematologic
Anaemia 34 (77.3) 5 (11.3) 39 (88.6)
Thrombocytopenia 29 (65.9) 6 (13.6) 35 (79.5)
Neutropenia 13 (29.5) 12 (27.3) 25 (56.8)
Non-haematologic
Skin toxic effect 31 (70.5) 6 (13.6) 37 (84.1)
Fatigue 25 (56.8) 5 (11.4) 30 (68.2)
Nausea 16 (36.4) 2 (4.5) 18 (40.9)
Vomiting 13 (29.5) 1 (2.3) 14 (31.8)
Diarrhoea 13 (29.5) 0 13 (29.5)
Anorexia 6 (13.6) 1 (2.3) 7 (15.9)
Infection
Biliary 0 7 (15.9) 7 (15.9)
Other 2 (4.5) 1 (2.3) 3 (6.8)
Oedema 3 (6.8) 0 3 (6.8)
Stomatitis 2 (4.5) 0 2 (4.5)
Liver dysfunction 0 2 (4.5) 2 (4.5)
Allergic reaction 2 (4.5) 0 2 (4.5)
Deep venous
thrombosis
1 (2.3) 1 (2.3) 2 (4.5)
Haemolytic uraemic
syndrome
0 2 (4.5) 2 (4.5)
Nephrotic syndrome 0 1 (2.3) 1 (2.3)
Other 9 (20.5) 3 (6.8) 12 (27.3)
Results are expressed as the worst toxic effect per patient, using the National
Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-
CTCAE) version 3.0.
Figure 1. (A) Kaplan–Meier analysis for progression-free survival in the
whole population. Among 44 patients, the median PFS was 5.8 months [95%
conﬁdence interval (CI) 3.6–8.5 months]. (B) Kaplan–Meier analysis for
overall survival in the whole population. Among 44 patients, the median OS
was 13.5 months (95% CI 9.8–31.8 months). (C) Kaplan–Meier analysis for
progression-free survival according to skin toxic effect. The median PFS
time was 7.7 months (95% CI 5.7–12.0 months) in patients with a skin toxic
effect ≥grade 2 and 3.3 months (95% CI 1.8–5.3 months) in patients with a
skin toxic effect ≤grade 1 (P = 0.05).
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months (95% CI 9.7–36.9 months) versus 9.9 months (95% CI
3.6–18.4 months): log-rank test; P = 0.104.
KRAS mutational status and response
Twenty-seven patients (61.4%) had sufﬁcient tissue for KRAS
mutational status determination. Twenty patients (74.1%) had
KRAS-wild-type tumours and 7 (25.9%) harboured exclusively
codon 12 mutations (S2, supplementary Table S2, available at
Annals of Oncology online). Of these seven, three had extra-
hepatic CCK and four intra-hepatic CCK. Five of seven had SD
as best response, the two others showed progression under
treatment. PFS and OS were not statistically different between
wild-type (6.7 and 14.8 months, respectively) and mutated
subjects (7.1 and 18.8 months): log-rank test; P = 0.616 and
P = 0.611, respectively.
discussion
Clinical trials have been impacted by the rarity of CCK. Despite
this, important advances have been accomplished over these last
years. Two phase III trials showed that Gem plus platinum salts
were superior compared with BSC or Gem [8, 15]. Furthermore,
two phase II trials exploring addition of monoclonal antibodies
to the doublet GEMOX also showed promising results. The
choice of EGFR as a therapeutic target in this study was based
on its known involvement, when activated, in oncogenesis and
tumour progression of CCK [9, 10]. Based on the available data
at time of our study design, we set the threshold for additional
beneﬁt of the gem-Ctx combination to a 40% PFS rate at 24
weeks. This objective was clearly met with 47% of our patients
being free from progression at 6 months. These results compare
favourably to the gem arm of the ABC-02 trial but not the
combination arm [8]. Median PFS obtained was also less than it
was found in the phase II trial combining Ctx with GEMOX
[11]. However, direct comparison of our results cannot be made
due to differences in eligibility criteria and study design. Indeed,
no patients with gallbladder adenocarcinoma were included in
our study. These might be clinically and biologically different
due to their different sensitivities to chemotherapy [14].
We assessed response according to skin toxic effect, as such
correlation was observed in colorectal cancer patients receiving
Ctx [16]. The majority of patients developed Ctx-related skin
toxic effect. Median PFS was more than doubled in patients who
experienced a skin toxic effect ≥grade 2; a ﬁnding already
reported, although with much less patients [11].
Similar to the ﬁndings of the BINGO trial [12], we did not
observe a statistically signiﬁcant correlation between KRAS
status and treatment efﬁcacy. KRAS mutations were detected in
25.9% of our patients, a result similar to that obtained in a
cohort of resected CCK patients [17]. In the Gruenberger et al.
trial [11], KRAS mutations were recorded in 3 of 27 patients,
Other trials report great variation in the prevalence of KRAS
mutations in biliary tract cancers, mostly due to small sample
size and detection methodology. Some published reports
suggest that the proportion of KRAS mutations is dependent on
CCK location [17, 18], which is difﬁcult to assess in our study
due to the small sample size. This should be further explored in
studies with larger cohorts.
The trial regimen was well tolerated with only six patients
(13.6%) withdrawing treatment due to toxic effect and without
any treatment-related deaths. However, we experienced a higher
than expected rate of serious renal toxic effect, with 2 HUS and
one patient with nephrotic syndrome; all three events evolved
favourably, requiring no renal support. HUS is a rare but well
recognized serious side-effect of gem, not reported in other
trials in CCK [19]. Its incidence is 0.25%–0.4% with gem and it
has not been reported with Ctx. The physiopathology of HUS
does no support an addictive effect of Ctx to Gem in this regard,
but we must acknowledge this has never been speciﬁcally
studied. This unexpected high toxic effect rate remains
unexplained.
In summary, the combination of gem-Ctx met our hypothesis
for efﬁcacy. However, as recent RCT failed to show a superiority
of platin-gem doublets with Ctx, it is uncertain if further
investigations in a prospective phase III RCT will be conducted.
Furthermore, a higher than expected renal toxic effect was
observed, warranting caution in future trials. Finally, as for
other types of cancer, establishing molecular (KRAS, hENT1)
[20] surrogate markers in a homogenous CCK population is
needed to better deﬁne those patients that will beneﬁt the most
from this combination therapy.
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Palliative radiotherapy and chemotherapy instead of
surgery in symptomatic rectal cancer with synchronous
unresectable metastases: a phase II study†
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Background: In stage IV rectal cancer, palliative surgery is often carried out upfront. This study investigated whether the
surgery can be avoided.
Patients and methods: Forty patients with symptomatic primary rectal adenocarcinoma and synchronous distant
metastases deemed to be unresectable received 5 × 5 Gy irradiation and then oxaliplatin-based chemotherapy. Before
treatment, 38% of patients had a near-obstructing lesion. The palliative effect was evaluated by questionnaires completed
by the patients.
Results: The median follow-up for living patients was 26 months (range 19–34). The median overall survival was 11.5
months. Eight patients (20%) required surgery during the course of their disease: seven patients required stoma creation
and one had local excision. Thirty percent of patients had a complete resolution of pelvic symptoms during the whole
course of the disease, and 35% had signiﬁcant improvement. In the subgroup with a near-obstructing lesion, 23% of
patients required stoma creation. In all patients, the probability of requiring palliative surgery at 2 years was 17.5% [95%
conﬁdence interval (CI) 13% to 22%), and the probability of sustained good palliative effect after radiotherapy and
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